

HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design

Marc H V Van Regenmortel

HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design

A Review of 20 Years of Research

Marc H V Van Regenmortel
School of Biotechnology
University of Strasbourg
Illkirch, France

ISBN 978-3-030-32458-2 ISBN 978-3-030-32459-9 (eBook)
<https://doi.org/10.1007/978-3-030-32459-9>

© Springer Nature Switzerland AG 2019

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG.
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Introduction

According to UNAIDS, during the year 2016, 36.7 million people on our planet were living with HIV, while 1.8 million people were newly infected by the virus. Since the start of the epidemic in the mid-80s, 35 million people have died of AIDS-related illnesses. Although considerable progress has been made in the treatment of HIV patients with antiretroviral drugs, it is now increasingly accepted that only an effective HIV vaccine will be able to end the AIDS pandemic. A few large-scale HIV vaccine trials have been undertaken, but none, so far, has elicited an adequate level of protection against infection.

It may seem paradoxical that although HIV has become the virus we know most about, after three decades of unparalleled high-quality research funded by billions of dollars, we are not yet sure whether a preventive HIV vaccine will ever be developed. This eBook brings together 24 scientific papers published by the author in the last 20 years which propose explanations for why it has been so difficult to develop a vaccine against what is probably the worst pandemic that has confronted humanity in recent times.

The book is divided into three parts: Immunochemistry (4 chapters), Reductionism (7 chapters), and the Search for a preventive HIV vaccine (12 chapters).

Part 1 consists of five chapters that introduce basic concepts in the immunochemistry of viral proteins which are important for understanding the nature of the reactions between viral antigens and antibodies. These are the key players involved in the immunological mechanisms that protect vertebrates against infections caused by viruses, although they are not the sole actors in immune systems that help fighting off virus infections. Another important player, known as the cellular arm of the immune system, consists of different types of immune cells such as T cells (i.e., thymus-derived), T regulatory cells, and dendritic cells which together with other immunoregulatory mechanisms are important for protecting organisms against viral infections. These other players will not be described in detail because it would have required writing an introduction to the whole of immunology which seemed not to be indispensable for understanding how vaccinologists have tried to harness neutralizing antibodies for protecting humans against HIV infection. The only immune cells

that will be described in detail are the so-called B cells (i.e., bone marrow-derived) which are cells that in their membranes possess B-cell receptors (BCRs) that correspond to antibodies possessing an additional tail that anchors them in the B-cell membrane. When a host is immunized with an antigen, certain BCRs in the host immune system interact with complementary antigens and the corresponding B cells become activated by interleukin-4 cytokines released by helper T cells. The B cells are then transformed into plasma cells that subsequently release antibodies which correspond to BCRs devoid of their anchoring tail.

The following two books are recommended to readers interested in a more comprehensive introduction to immunology: *Immunity* (Paul 2015) and *Immunity: The Making of a Modern Science* (Gallagher et al. 1995).

Part 1. Immunochemistry

Chapter 1 describes the chemical structure of small regions in proteins, called epitopes, which are recognized by the binding sites of antibodies, called paratopes. So-called discontinuous epitopes in a protein are made up of 10–20 amino acid residues located on 3–5 separate segments of the peptide chain that are brought together at the protein surface by the folding of the chain. Continuous epitopes are short peptide fragments of 5–8 residues which are often part of a larger discontinuous epitope and which can bind to antibodies raised against the protein antigen. Classifying epitopes as either continuous or discontinuous may give the erroneous impression that the smallest units of immunological recognition are amino acid residues, although it is at the level of individual atoms that interactions take place. Paratopes consist of 10–25 residues assembled from short stretches of residues located on the six complementarity determining regions of antibodies which together form a discontinuous binding site. Short peptide regions of 3–5 residues present on these six hypervariable antibody loops are often able on their own to bind to continuous epitopes, and these short loop sequences could then be viewed as continuous paratopes. Such binding is usually caused by the type of hydrophobic complementarity between hydrophilic and hydrophobic residues that is commonly observed between the sense and antisense peptides encoded by complementary sense and antisense messenger RNA strands. This remarkable pattern arises because RNA codons (sense) and anticodons (antisense), without any exception, always code for amino acids of opposite hydrophobicity, i.e., either hydrophilic or hydrophobic residues that have a strong affinity for each other. This phenomenon gave rise to the hypothesis that the genetic code initially evolved to favor the simultaneous emergence from complementary RNA strands of sense and antisense peptides that could assume the role of receptors with their complementary ligands (Biro 2005).

Other protein epitopes of 5–10 residues, known as mimotopes, are able to react with short paratope sequences from antibodies raised against the protein even if they show little or no sequence similarity with the protein used to induce the antibody. This type of binding arises when the two peptides possess opposite hydrophobic patterns of hydrophilic and hydrophobic residues in their respective sequences.

Chapter 2 analyzes the common assumption that our current knowledge of the chemical structure of epitopes and paratopes should make it possible to apply

molecular design strategies for developing synthetic vaccines. The major difficulty that has been encountered in such attempts is that the capacity of the immune system to induce a protective neutralizing antibody response depends more on numerous biological properties and regulatory mechanisms of the immune system of the host than on the elucidated chemical complementarity of single epitope–paratope pairs. Since a large number of necessary preconditions in the immune system have to be met before neutralizing antibodies can be obtained by vaccination, there are plenty of reasons why the molecular design of an HIV vaccine is not at present a realistic scientific enterprise.

Chapter 3 summarizes the numerous attempts that have been made to develop synthetic peptide vaccines by making continuous epitopes adopt the structures observed when viruses are bound to neutralizing antibodies. Although peptide vaccines would have the advantage of increased safety and stability as well as lower cost, it is remarkable that hundreds of studies using synthetic peptides had not led in 2006 to a single synthetic peptide vaccine marketed for human use (Hans et al. 2006).

A major reason for all these repeated failures is the fact that investigators relied mainly on continuous epitopes that are mostly short linear peptide fragments of more complex discontinuous epitopes which are the large majority of neutralization epitopes found in viral proteins. It must also be stressed that most peptides are immunogenic in the sense that they readily elicit antibodies that react with the peptide immunogen, although they do not cross-react with the parent protein and are not able to neutralize viral infectivity.

Chapter 4 analyzes the binding specificity of antibodies that arises from a limited number of residues in the six antigen-binding regions (ABRs) that together form the numerous paratopes present in every antibody molecule. Each ABR differs significantly in its amino acid composition and tends to bind different types of amino acids present at the surface of proteins. In spite of these differences, the combined collective preference of the six ABRs does not allow epitopes to be chemically distinguished from the remainder of the antigen surface. When the amino acid composition of the six ABRs in 200 different antibody-antigen complexes was examined, it was found that there was no noticeable difference between the amino acid composition of epitopes and that of the entire protein surface. No amino acid was significantly overrepresented in epitope regions compared to the rest of the protein surface, and since the entire surface is an antigenic continuum, most of the surface could actually be part of epitopes. These findings explain why the many algorithms that were developed over the last 20 years for predicting the location of epitopes at the surface of proteins were not very successful (Van Regenmortel 1999a, pp. 53–68).

Antibody polyspecificity refers to the fact that every antibody molecule always harbors numerous paratopes that allows it to bind to a large variety of epitopes present in different antigens. Antibody heterospecificity arises when an antibody reacts better with another antigen than with the one used to raise the antibody. Such a phenomenon is not rare and can lead to the unexpected finding that the antibody appears to have been elicited by an antigen with which it is unable to react, although

this may only reflect the fact that the binding reactivity was below the detection level of the immunoassay that was used. Antibody heterospecificity explains the common observation that early antisera obtained soon after immunization with any antigen frequently contain levels of total induced immunoglobulins that far exceed the level of antibodies able to react with the immunizing antigen. The heterospecificity of antibodies demonstrates that immunogenicity and antigenic reactivity are not always present simultaneously in the same region of a protein which is one of the reasons why the strategy of structure-based reverse vaccinology has not been successful for developing an effective HIV vaccine.

Part 2. Reductionism

Chapter 5 analyzes the appeal of reductionist thinking for trying to understand the relationship between the structure and function of antibody molecules. The structure of a protein arises from the selective attention to the visual experience of that object at a specific time. Such a static definition excludes the dimension of time and conceals the fact that pictures of biomolecules are visual time-slides of dynamic systems. The structure of a binding site, furthermore, cannot be identified independently of its interaction with a ligand since these two relational entities are defined by their mutual steric complementarity.

Epitopes and paratopes are thus not intrinsic constituents of proteins and antibodies that exist independently of this relational nexus. Only a small fraction of the residues that are assigned by functional assays to a binding site contribute to the binding free energy and residues that are not in contact at the interface can also affect binding affinity. The reductionist approach of analyzing the structure of epitope–paratope complexes by crystallography has therefore been of limited use for designing functional entities that will exhibit a neutralizing activity when placed in the context of a particular cellular environment in the infected host.

Chapter 6 analyzes the reductionist expectation that assumes that the biological phenomenon of protection against infection achieved with neutralizing antibodies can be reduced to the level of chemistry. It is not possible to predict the neutralizing activity of an antibody simply from its chemical structure because protective immunity only occurs in the context of whole organisms since tissues and organs cannot be vaccinated. The structures of epitopes and paratopes present in a crystallographic complex correspond to a terminal state after a dynamic process of induced fit and conformational selection, and they give little information on the epitope conformation present in the immunogen-bound BCR that triggered the appearance of a neutralizing antibody activity. This activity is not selected by the BCRs during immunization since the neutralizing capacity of the antibody will be revealed only subsequently in the context of a complex cellular environment.

Chapter 7 summarizes the debates that took place during a conference on Reduction and Emergence held in Paris in 2003. William Wimsatt explained that a reductionist starts by choosing and designating a system for analysis which partitions the world of study into that system and its environment. Assumptions will be made about which variables must be controlled or randomized and the description of the environment will be greatly simplified compared to the description of the entities

internal to the system under study. Fitness, for instance, will be described as if it were a property of phenotypes or genes and the fact that it is a relation between organism and environment will tend to be ignored. When environmental variables are not monitored, the investigator will be unaware of the context dependence of biological phenomena.

Causal explanations are reductive because one factor is singled out for attention and is given undue explanatory weight on its own. However, in biological systems any observed effect always results from a complex network of interactions and an explanation in terms of a single cause is never satisfactory. Although molecular biology has clarified the intricate mechanisms that allow genes to be translated into proteins, it has provided little insight on the innumerable causal chains that link genes to phenotypic traits. A common fallacy is to assume that the function of a gene is to produce whatever the system fails to do when that gene is absent. As a result, genetic determinism has not been able to unravel the complex series of events that link phenotypes to genes.

Chapter 8 discusses why it is so difficult to analyze the complexity of biological systems in a satisfactory manner. One reason is that complex systems always possess emergent properties that are absent when the parts are studied separately and which cannot be predicted or deduced from the properties of the parts. Interactions between the parts as well as inputs from the environment give rise to novel features such as network behavior that lead to the characteristic homeostasis of biological systems. Homeostasis allows biological systems to maintain a dynamic stability as well as an ability to self-repair which is largely independent of specific control mechanisms.

Biological systems cannot be described adequately without referring to the functional roles that their constituents play in keeping them alive. Darwinian evolution explains the existence of a present-day function by saying that it exists because it contributed to the reproductive fitness of the organism in the past. Biologists thus favor evolutionary explanations for presently observed structures and do not look for structural explanations for a presently observed function.

Design is defined as the deliberate and intelligent conceiving of an artificial thing or process. Since the human mind is the most efficient goal-directed system that exists, human intentionality is perceived as the cause of all purposive human actions. This leads to the anthropomorphic fallacy that the behavior and activities of all biological systems are explainable in terms of goals and purposes. Since any functional part that contributes to the working of the system can be interpreted as achieving a certain goal, this leads to the view that the system was designed by a thinking mind to function in a preordained way. This encourages the use of metaphors of end-directed features for describing biological processes in terms of design, purposes, and functions. It also encourages the expectation that the human mind has the capacity of intentionally designing an integrated immunological system that will protect against HIV infection. Since natural selection has not yet succeeded in achieving such a feat, there is considerable skepticism that a preventive HIV vaccine can be rationally designed by reverse engineering (Green 2013).

Chapter 9 discusses the negative impact that reductionist thinking has had on HIV vaccine development. Although methodological reductionism which dissects

biological systems into their constituent parts was initially very successful in molecular biology, it was later found to possess many limitations for studying complex biological systems. For instance in the search for an effective HIV vaccine, the use of Mabs for dissecting HIV immune responses made investigators focus on individual epitopes as elicitors of neutralizing antibodies. This made them neglect the synergistic effects that are observed in polyclonal immune responses directed against individual epitopes of a major HIV antigenic site when a variety of neutralizing antibodies elicited by different epitopes are acting together.

Reductionist thinking also blurs the distinction between the chemical nature of antigenicity and the biological nature of immunogenicity. This leads to the assumption that when an HIV epitope is reconstructed by rational design to better fit a neutralizing antibody, it produces an immunogen able to elicit polyclonal antibodies with the same neutralizing capacity as the neutralizing Mab. Reductionism also fosters the belief that protection against HIV infection can be fully analyzed at the level of molecular interactions between an epitope and a paratope which in most cases is the only parameter that vaccinologists take into account when they design a vaccine. Numerous features of the host immune system are crucial for the induction of neutralizing antibodies, and because they ignored these contributory factors, investigators became engaged in hundreds of abortive attempts to transform HIV epitopes of known structure into effective vaccines. Using a convergence argument, it has been argued that so many negative outcomes justify the conclusion that the reverse vaccinology approach that was used is not capable of developing a preventive HIV vaccine.

Chapter 10 responds to a commentary (King 2016) which rejected the convergence argument that reverse vaccinology is actually unable to develop an effective HIV vaccine. It was argued that such a convergence argument is based on inductive reasoning from a limited number of cases that can never lead to a logically certain conclusion. It is indeed true that no amount of experimental evidence can ever lead to the absolute certainty achievable by deductive reasoning and the convergence argument is therefore only a backup argument. The fundamental reason why reverse vaccinology failed in the case of HIV is that it did not have a sound theoretical basis derived from our current knowledge of immunological specificity and of anti-HIV immune responses (see also Chaps. 4 and 21). King (2016), however, was right to point out that it may be considered unethical to pursue attempts to develop an HIV vaccine by a consistently unsuccessful approach if scarce resources could be used more effectively to combat the AIDS epidemic by other approaches.

Chapter 11 discusses the nature and consequences of biological reductionism in the immunological study of infectious diseases. The major message of this review is that useful information does not depend only on data input but requires procedures that include both reductionist and non-reductionist steps in order to detect distinct patterns that subsequently need to be examined experimentally.

Part 3. The Search for a Preventive HIV Vaccine

Chapter 12 discusses the limitations of structure-based design of HIV vaccine immunogens which arise from (1) misconceptions regarding the nature of epitopes,

(2) disregarding the analytical bias that arises when Mabs are used to dissect the structure of antigens, and (3) assuming that effective HIV vaccine immunogens can be identified by analyzing the structure of epitope–paratope complexes by X-ray crystallography. Epitopes and paratopes are relational entities defined by their mutual complementarity, and they depend on each other for acquiring a recognizable identity. Once a neutralizing Mab has been isolated from the serum of an infected individual, it usually becomes conceptually associated with a single discrete epitope. However, since an antibody always contains numerous paratopes, there is no reason why a vaccine containing that one particular epitope should also be able to induce a polyclonal, neutralizing antibody response. A large number of paratopes binding to the major antigenic sites of the HIV envelope (Env) have been thoroughly investigated, but this has not helped the design of an HIV vaccine.

Chapter 13 discusses the two different meanings of the term reverse vaccinology used for developing bacterial and viral vaccines. Rino Rappuoli (2001) developed a strategy, based on bioinformatic analyses of entire bacterial genomes, for identifying all the antigens that a bacterial pathogen is able to express. He called it reverse vaccinology because he started from the genome instead of from the organism for establishing which surface-exposed proteins should be investigated as potential vaccine immunogens. Whereas classical approaches investigate only the small number of purified antigens that can be obtained by fractionating bacterial extracts, reverse vaccinology made it possible to evaluate hundreds of expressed bacterial proteins and to develop successful bacterial vaccines.

In virology, the reverse vaccinology approach of Burton (2002) refers to a completely different strategy. Instead of the usual approach of generating antiviral antibodies by vaccination, it uses a so-called reverse approach for trying to generate a vaccine from the known 3D crystallographic structure of one paratope identified in neutralizing anti-HIV antibodies. From the structure of epitope–paratope complexes, attempts are made to elicit neutralizing antibodies by reverse engineering epitopes in order to endow them with the capacity to induce neutralizing antibodies.

Calling these two completely different strategies “reverse vaccinology” makes little sense, and it would have been preferable to call them genome-based and structure-based reverse vaccinology, respectively. Calling them reverse vaccinology 1 and reverse vaccinology 2 is also not particularly instructive because it obscures the fact that the genome-based approach has been successful, whereas the structure-based approach has systematically failed for more than 20 years (see Chap. 22).

Chapter 14 describes the structure of many continuous and discontinuous HIV epitopes identified in Env spikes and of their complementary paratopes as well as the many unsuccessful attempts that were made to modify the epitope structures in order to improve their vaccine potential.

Chapter 15 summarizes the discussions that took place during a workshop held in Baltimore in 2013. The participants proposed several new research paradigms that better fit our increasing knowledge of HIV immunopathology and which could possibly be more helpful for guiding future HIV vaccine research than past unsuccessful approaches. It was stressed that the development of a successful HIV vaccine required new prescriptive knowledge in the form of a practical invention rather than

increased propositional and fundamental knowledge about the inner workings of the immune system.

Chapter 16 is the Introductory Editorial to a Research Topic entitled “Paradigm changes are required in HIV vaccine research” published in 2014. In his influential book *The Structure of Scientific Revolutions*, Kuhn (1962) argued that researchers in every field of scientific enquiry are always guided by theoretical assumptions, pre-suppositions, and hypotheses that constitute the prevailing scientific paradigm under which they operate at a given time. This paradigm commits them to using certain strategies and experimental approaches considered to be essential for trying to solve the problem at hand. The implicit presuppositions that gave rise to a particular paradigm are rarely stated, and when investigators obtain results that are not compatible with the hypothesis underlying the paradigm, they may fail to appreciate that the paradigm has been refuted and should be abandoned or revised. Scientists, however, tend not to abandon their guiding paradigm when they obtain contradictory results because their main goal is not to try to confirm the validity of the assumptions underlying the paradigm they follow. Instead, they will invent new *ad hoc* hypotheses for resolving contradictions between theory and experimental observations which allow them to pursue their investigations within the framework of their chosen paradigm, even at the risk of pursuing unfruitful lines of investigation. The following five paradigms had a detrimental effect on HIV vaccine research because they were based on erroneous assumptions: (1) Vaccine immunogenicity can be predicted from viral antigenicity, (2) there is a primary and intrinsic epitope for each BCR and its corresponding antibody, (3) unraveling large numbers of antibody maturation pathways will necessarily allow the identification of numerous HIV-1 immunogens suitable for repeatedly vaccinating large populations of genetically variable individuals, (4) rational design of HIV-1 immunogens is more effective than classical empirical screening of immunogens, and (5) reactions of viral antigens with protective Mabs are more specific than the combined reactivity of antibodies in a polyclonal antiserum.

Chapter 17 describes in detail one of the main reasons for the failure of structure-based reverse vaccinology (SBRV) to develop a preventive HIV vaccine. Adepts of SBRV tend to focus their attention mainly on residues in HIV epitopes and paratopes that make contact with each other, and they ignore the fact that the binding activity of these sites is often influenced by structural features distant from the sites themselves. In addition, the structure of the epitopes and paratopes observed in the complex is the result of the mutual adaptation and induced fit that occur when the partners interact during the immunization process and they are unlikely to correspond to the structure of the free sites. Another common assumption is that all antibodies and Mabs are monospecific for a single epitope, although they always contain numerous paratopes able to bind a variety of epitopes as well as autoantigens with various degrees of fit (Mouquet and Nussenzweig 2012). Once it is accepted that the epitope structure observed in an nMab-HIV1 Env complex is only one of the many epitopes that can be accommodated by a polyspecific Mab, there is no reason to assume that the epitope of known structure is the one that elicited the nMab. The central assumption

of SBRV is therefore invalid since the one epitope whose structure was established is not necessarily able to elicit antibodies that neutralize HIV-1.

Chapter 18 is a commentary on the paper published by Andrieu et al. (2014) in the Research Topic mentioned in Chap. 16. These authors reported results obtained in Chinese macaque experiments that explored a new vaccine concept aimed at inducing tolerance to the simian immunodeficiency virus (SIV). They administered inactivated SIV intragastrically together with living bacterial adjuvants such as *Lactobacillus* bacteria with the goal of inducing tolerance to SIV antigens. Although this approach did not elicit SIV-specific antibodies nor cytotoxic T-lymphocytes, it protected 23 out of 24 experimental animals from mucosal and parenteral challenges. A previously unrecognized population of non-cytolytic MHV 1b/E-restricted CD8+ regulatory T cells was identified which suppressed the activation of SIV-positive CD4+ lymphocytes (Lu et al 2016). In view of the dearth of novel approaches in HIV vaccine research, such intriguing and unexpected results clearly need to be confirmed or refuted by further investigations with Chinese macaques (Carnathan et al. 2018).

Chapter 19 analyzes the common assumption that Mabs derived from HIV-infected individuals are the most effective reagents for dissecting antibody responses to HIV infection. It is often not appreciated that the apparent specificity of a Mab very much depends on the selection process that was used to obtain it. For instance, when a Mab is selected for its ability to bind a linear peptide in a peptide library that mimics a viral epitope, it is not astonishing that it will bind more strongly to the selecting peptide than to the virions that initially induced the Mab production in the infected host. Since most Env epitopes are discontinuous, their binding activity cannot be assessed by extracting all the constituent epitope residues from the protein to show that they are able to bind on their own when they are not embedded in the native protein structure. A short linear peptide that is part of such a discontinuous epitope may of course retain some binding activity, and this may lead to the peptide being called a continuous epitope.

It is often assumed that Mabs are better reagents for studying immune responses to HIV infection than polyclonal antibodies in spite of the fact that most effective antibody responses are polyclonal and directed to the multiple neutralizing epitopes that constitute the antigenic sites of HIV Env. Although the paratope structures in many nMabs have been elucidated, this knowledge has not helped the design of effective vaccine immunogens. Although it is possible by rational design to improve the ability of one epitope to bind to one paratope in an nMab (i.e., improving the antigenicity of a protein), the claim that what is being designed is an HIV vaccine immunogen able to trigger a protective immune response is the basic flaw of the SBRV approach because it assumes that when an HIV epitope reacts with an nMab, it should also be able to induce similar neutralizing antibodies in an immunized host.

Chapter 20 summarizes the discussions that took place during a workshop on new strategies in HIV vaccinology held in Rome in 2016. Eleven participants were asked to respond to the following five questions: (1) What new approaches should be followed in HIV-1 vaccinology? (2) Should HIV-1 inactivation be reconsidered? (3) Can therapeutic vaccines help the development of a preventive HIV vaccine?

(4) Can therapeutic vaccines lead to a functional cure? (5) If you had the authority to do it, what vaccine concepts would you support for testing? The variety of answers that these questions elicited clearly indicates that novel research strategies for developing a possible HIV vaccine are urgently needed.

Chapter 21 explains the many reasons why the rational design of a preventive HIV-1 vaccine by SBRV failed to deliver an effective vaccine. The review describes in considerable detail the structure and dynamics of epitopes and paratopes as well as the considerable improvement of our understanding of antibody specificity in recent years. It has for instance been clearly demonstrated that the amino acid compositions of epitopes and of the entire surface of proteins are very much the same, which finally explained why it had not been possible for more than 25 years to predict accurately the location of epitopes in proteins on the basis of amino acid propensities such as hydrophilicity or accessibility (see Chap. 4).

Although it is frequently stated that rational design is the best strategy for developing new vaccines, this does not seem to be the case for HIV vaccine development. Rational design applies mainly to drug design when candidate molecules are designed to fit the 3D structure of a biological target in order to bind to it with high affinity and inhibit its biological function. Such a computer-assisted approach based on molecular docking succeeds because the complementarity between a drug and its target molecules is fairly unique. In contrast, molecular recognition processes between an antigen and the many antibodies that are able to bind to it are much less specific than drug–receptor interactions mainly because of the conformational flexibility of epitopes and paratopes, the degeneracy of the immune system, and the polyspecificity of antibodies. It also seems inappropriate to use design terminology for describing the SBRV attempts made by investigators when they try to have an antigen produce protective antibodies since they only improve the antigenic binding capacity of viral epitopes and not their immunogenic capacity to trigger the immune system to elicit protective antibodies. SBRV disregards accepted immunological theory pertaining to the degeneracy of the immune system and the polyspecificity of antibodies and also underestimates the extreme plasticity of the HIV Env protein as well as the extensive conformational flexibility of epitope and paratope binding sites.

Chapter 22 points out that when HIV epitopes are called vaccine immunogens, this could be interpreted to mean that they are able to generate immune responses in the immunized host, although it should be evident that they only trigger in the host a series of reactions with BCRs that eventually may lead to the immune system producing antibodies, some of which may be neutralizing. The type of antibody that is produced depends on numerous properties of the immune system such as its antibody gene repertoire, the presence of helper and suppressor T cells, the secretion of cytokines, self-tolerance, and a variety of other immunoregulatory mechanisms. Vaccinologists who claim to be designing a vaccine immunogen by SBRV tend to ignore these contributions from the immune system because they focus on the recognition processes between single epitope–paratope pairs instead of investigating by trial and error which components of the immune system must be controlled to ensure that neutralizing antibodies are elicited. Only when it was found that HIV Env

epitopes recognized by affinity-matured antibodies obtained from HIV chronically infected individuals did not bind the germline predecessors of these antibodies was it realized that potential vaccine immunogens may only be discovered if one took into account the slow but extensive antibody maturation that is needed to obtain neutralizing antibodies. Additional immune correlates of protection are needed to guide HIV vaccine development, but these can be inferred only retrospectively when an efficacious vaccine has been developed empirically. Since we know very little about which features of the immune system regulate the production of protective antibodies, it seems unavoidable that empirical vaccination trials will continue to be required when trying to develop an effective HIV vaccine.

Chapter 23 describes the nature of the inverse problems that vaccinologists need to solve when trying to develop an HIV vaccine. Inverse problems differ from the usual direct problems in science that are solved by determining experimentally what are the effects that follow certain causes. Biological systems are made up of successive levels of increasing complexity from genes to RNAs, proteins, organelles, cells, tissues, and organs. At all these different levels, innumerable interactions occur involving genetic, epigenetic, biochemical, and physiological factors which nowadays are mainly analyzed using system biology approaches. Numerous bottom-up and top-down causal links occur across the different constituents and levels of the immune system, and as a result, our theoretical understanding of the mechanisms responsible for the appearance of neutralizing antibodies against HIV is practically nonexistent.

We are unable to imagine what are the multiple causes that could lead to protection against HIV infection because we lack an integrated theoretical model of the entire immune system. Such a model is actually required for conceiving plausible solutions to inverse problems which then need to be verified experimentally.

Solving an inverse problem may for instance require developing a model that could explain the multiple causes that produce a desired effect such as the absence of a deleterious HIV infection in elite controllers, and then subsequently demonstrating that by adjusting certain parameters in the immune system, the desired outcome can be obtained in a genetically heterogeneous population.

Whereas many direct problems can be solved because of our knowledge of the biological mechanisms that bring about certain effects, this is not feasible in the case of inverse problems that cannot be solved in this manner. Because of the complexity of the immune system, vaccinologists mostly do not have access to all the information that would be required in order to make entirely rational decisions based on a complete knowledge of all the relevant parameters. Since several inverse problems may first need to be solved at different levels of the immune system, it may in fact turn out not to be possible to rationally develop an HIV vaccine in this manner. In the last 20 years, investigators have mainly studied the rather ineffective antibody responses that occur several years after the initial acute phase of HIV infection, although these antibodies are usually unable to control the infection in the individuals from whom they had been isolated.

Since the initial acute phase of HIV infection is caused by so-called transmitter/founder (T/F) viruses that are not predominant in the individual donors, it could be

argued that the immune response against T/F viruses may be most relevant for developing a preventive vaccine. Since new and more reliable inactivation methods have been developed that could be applied to T/F viruses, immunization studies with inactivated T/F virions should be undertaken in the near future. Chemically inactivated immunogens have been used successfully for developing vaccines against several animal retroviruses (Beczowski et al. 2015), but this approach is still considered to be too risky in the case of HIV. It is nevertheless astonishing that such a time-honored strategy has never been tested as a possible way to stop the AIDS epidemic (Sheppard and Dorman 2015; Rios et al. 2016).

Chapter 24 briefly discusses the complexity of biological systems and its compatibility with determinism. Although determinism assumes that every natural phenomenon is entirely determined by preexisting causes, in biological systems no single event can ever be said to be the necessary and sufficient cause for a biological effect to occur. Numerous contributory causes always exist, and it is not possible to single out one factor and give it undue explanatory weight on its own (Van Regenmortel 2007).

Biological systems consist of hierarchical compartments of increasing complexity which all communicate with each other via translocating molecules. This organization leads to upward as well as downward causality, for instance when the constituents at the lower levels are controlled by new emergent properties that arise at the higher levels (Van Regenmortel 2012). One of the aims of systems vaccinology (Pulendran 2014) is to understand how emergent immunological phenomena arise from the multiple interactions that occur in complex immune systems. At each successive level of organization from genes to proteins and to cellular tissues, innumerable interactions occur between genetic, epigenetic, biochemical, and environmental factors which need to be analyzed separately before they could be integrated in a functional complex system. Numerous individual, fully deterministic causal processes follow separate trajectories, but when they impede each other, following a contingency pattern, unpredictable effects are obtained. Our understanding of the entire integrated system remains severely limited because of our inability to measure accurately the on-and-off-kinetic rates of individual interactions. The reason for this is that the kinetic constants of an interaction are highly dependent on the active concentration of the two partners in their cellular environment, a parameter that is extremely difficult to measure accurately (Richalet-Secordel et al. 1997; Zeder-Lutz et al. 2009). The active concentration is always considerably lower than the nominal concentration (that can be measured for instance by spectrophotometry), because of the inevitable presence of an unknown amount of incorrectly folded molecules. As a result, kinetic measurements of the numerous individual interactions are extremely inaccurate which prevents us from understanding the dynamics of fully integrated complex immune systems.

Physicists used to believe that the universe was ruled by mathematical laws that would make it possible to predict the future behavior of a system if one had an intimate knowledge of its initial conditions. That assumption became untenable in the twentieth century with the development of chaos theory which established that extremely small differences in the initial conditions of a dynamic complex system

had a huge impact on the subsequent state of the system (Du Sautoy 2016). Making very precise quantitative measurements of the innumerable initial conditions of a complex biological system is of course even more unattainable than in the case of physical systems, and we may have to accept that making accurate predictions about the future states of a dynamic biological system remains completely intractable (Green 2015).

Contents

Part I Immunochemistry

What Is a B Cell Epitope	3
Introduction	3
Types of Epitopes	3
Continuous Epitopes	4
Discontinuous Epitopes	5
Additional Epitope Types	6
Mimotopes	7
Epitopes Are Relational Entities and Not Intrinsic Features of Proteins	8
Antigenic Cross-Reactivity and Antibody Specificity	9
Antigens Versus Immunogens	12
Epitope Prediction	13
Molecular Design Versus Empirical Discovery in Peptide-Based Vaccines: Coming to Terms with Fuzzy Recognition Sites and Ill-Defined Structure-Function Relationships in Immunology	17
Introduction	17
Rational Design Versus Empirical Discovery	18
The Fuzzy Nature of Structure-Function Relationships	19
Empirical Discovery Rather than Molecular Design Will Bring Forth Synthetic Vaccines	20
Immunogenicity Is Not Amenable to Molecular Design	23
Conclusion	23
Synthetic Peptide Vaccines and the Search for Neutralization B Cell Epitopes	25
Introduction	25
The Nature of Protein Epitopes	26
Neotopes and Mimotopes	28
Antibody Multispecificity	28

The Operational Bias of Monoclonal Antibodies	30
The Cross-Protective Immunogenicity of Peptides cannot Be Predicted from their Antigenicity	33
Epitope Prediction and the Synthetic Reconstruction of Discontinuous Epitopes	34
Conclusion	36
Specificity, Polyspecificity and Heterospecificity of Antibody-Antigen Recognition	39
Introduction	39
Antibody Specificity	40
The Structural Basis of Paratope-Epitope Recognition	42
The Epitope Prediction Conundrum	48
Antibody Polyspecificity	50
What Are the Implications of Antibodies Being Able to Bind Viral and Microbial Antigens as Well as Self Antigens?	53
Antibody Heterospecificity	54
Part II Reductionism	
Reductionism and the Search for Structure: Function Relationships in Antibody Molecules	59
Introduction	59
Structures	60
Functions	61
The Use of Functional Language in Biology	62
Causal Explanations Versus Functional Explanations	63
Looking for Structural Correlates of Binding Sites	66
Predicting the Binding Properties of Antibodies	67
Knowledge of Structure: Activity Correlates in Antibodies are of Little Use in Vaccine Design	68
Reductionism and Complexity in Molecular Biology: Scientists Now Have the Tools to Unravel Biological Complexity and Overcome the Limitations of Reductionism	71
The Most Extreme Manifestation of the Reductionist View Is the Belief that Is Held by Some Neuroscientists that Consciousness and Mental States Can Be Reduced to Chemical Reactions that Occur in the Brain	72
Anti-Reductionists Regard Biology as an Autonomous Discipline that Requires Its Own Vocabulary and Concepts that Are Not Found in Chemistry and Physics	73
It Remains True that Human Disease Is Best Studied in Human Subjects . . .	74
Vaccination Is Firmly Anchored in the Biological Realm and Cannot Be Reduced to the Level of Chemistry	75
The Impossibility of Reducing Biology to Chemistry Is Responsible for the Lack of Success in Developing Structure-Based Vaccines	76

Extreme Holism, According to Which Everything Is Connected, Certainly Does Not Provide a Methodological Alternative	78
Editorial: Biological Complexity Emerges from the Ashes of Genetic Reductionism	79
The Limits of Reductionist Explanations in Biology	80
Causal Explanations Versus Functional Explanation	81
The Rejection of Genetic Reductionism and Determinism	82
Cancer as a Tissue Organization Problem	83
Molecular Neuroscience: The Last Bastion of Ruthless Reductionism	84
The Rational Design of Biological Complexity: A Deceptive Metaphor	87
Reductionism, Emergence, and Complexity	87
The Nature of Biological Systems	88
Function and Functional Language in Biology	89
Human Intentionality and the Design Metaphor	90
The Bogus Scientific Claims of the Intelligent Design Movement	92
The Lure of Rational Design Claims	93
Complex Causal Connections Are the Rule in Biological Systems	94
A Case Study: The Rational Design of Synthetic Peptide Vaccines	96
How Can Systems Biology Help to Unravel the Immune System?	100
Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking	103
Introduction	103
Antibody Polyspecificity and the Relational Nature of Epitopes and Paratopes	104
Causation and Explanation in Biology and Immunology	107
Reductionism and Emergence in Immunology	110
Human Intentionality and Rational Design Strategies	112
Reverse Vaccinology and the Rational Design of HIV-1 Antigens	114
The Bottleneck of Antibody Affinity Maturation	119
Systems Biology and the Identification of Immune Correlates of Protection	121
Scientific Understanding Arises from the Ability to Successfully Manipulate the Immune System	123
Concluding Remarks	125
Commentary: Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking	127
Nature and Consequences of Biological Reductionism for the Immunological Study of Infectious Diseases	131
Reductionism and its Historical Background	131
Reductionism-Related Errors and Information Loss	132
Toward Remedial Strategies (I): The Properties of Infectious Disease-Related Data	134

Toward Remedial Strategies (II): Methodological Foundations	134
Visualization of Reductionist and Non-Reductionist Paradigms	136
Non-Reductionist Applications	138
The Future: Integration of Non-Reductionist and Reductionist Operations	139
Conclusion	139

Part III The Search for a Preventive HIV Vaccine

Limitations to the Structure-Based Design of HIV-1 Vaccine

Immunogens	143
Introduction	143
The Nature of Protein Epitopes	144
Viruses Possess Quaternary Structure-Dependent Epitopes	144
Epitopes and Paratopes Are Relational Entities	145
Mabs Introduce a Bias in Antigenic Analysis	146
Antigenic Sites of HIV-1	147
The CD4-Binding Site	148
The CD4-Induced Antigenic Site	149
The V3 Antigenic Site	149
The MPER Antigenic Site	150
The Glycan Antigenic Site	151
Studies with HIV-1 Mabs in the Context of Vaccine Development	151
V3 Epitopes	151
MPER Epitopes	153
Effective Vaccine Immunogens Cannot Be Predicted from the Structure of Epitope-Paratope Complexes	154
Does Structure-Based HIV-1 Vaccine Design Amount to Reverse Vaccinology?	155
Antigenicity Versus Immunogenicity	156
Alternatives to the Rational Design of Vaccines	157

Two Meanings of Reverse Vaccinology and the Empirical Nature of Vaccine Science

Requirements for Empirical Immunogenicity Trials, Rather than Structure-Based Design, for Developing an Effective HIV Vaccine	163
Introduction	163
The Nature of Protein Epitopes	164
Discontinuous Epitopes	165
Continuous Epitopes	165
Neotopes and Cryptotopes	167
Mimotopes	168
What Do Mimotopes Mimic?	169
The Specificity of Antibodies Is Limited Rather than Absolute	170
Degeneracy of the Immune System and Fuzzy Recognition Sites	171
Epitopes and Paratopes Are Relational Entities	173

Epitopes and Antigenic Sites	173
Antibody Heterospecificity	174
Specificity Versus Discrimination Potential	174
Antibody Specificity and Affinity	175
Discontinuous Epitopes Cannot Be Extracted from Their Protein Environment in Order to Be Used as Vaccine Immunogens	175
The Unsuccessful Search for Immunogens Was Able to Elicit B12-like Antibodies	176
Continuous Epitopes of Viral Proteins Are Not Effective Vaccine Immunogens	179
The Special Case of Terminal Regions in Proteins	180
The HIV-1 V3 Antigenic Site	181
One of the Many Hurdles to Be Overcome by an HIV-1 Vaccine Is the Antigenic Variability of the Virus	182
Rational Design Versus Empirical Immunogenicity Trials in HIV-1 Vaccine Development	183
Conclusions	187
 Paradigm Changes and the Future of HIV Vaccine Research: A Summary of a Workshop Held in Baltimore on 20 November 2013	
Introduction	189
A New Paradigm Advocating Basic Research	190
From Basic and Applied Research to Technological Innovation	191
 Editorial: Paradigm Changes Are Required in HIV Vaccine Research	
Assumption No. 1: Vaccine Immunogenicity Can Be Predicted from Viral Antigenicity	200
Assumption No. 2: There Is a Primary and Intrinsic Epitope Specific for Each B Cell Receptor and Its Corresponding Antibody	200
Assumption No. 3: HIV-1 Epitopes Recognized by Mature nMabs Isolated from HIV-1 Infected Individuals After a Lengthy Process of Antibody Affinity Maturation Will Be Able to Induce a Protective Immune Response in Naive Individuals	201
Assumption No. 4: The So-Called Rational Design of HIV-1 Immunogens Is More Effective than the Classical Trial-and-Error Screening of Immunogens Used in the Past for Developing Successful Vaccines	201
Assumption No. 5: Reactions of Viral Antigens with Mabs Are More Specific than the Combined Reactivity of Polyclonal Antibodies Found in an Antiserum and Are Able to Inform Vaccine Design	202

An Outdated Notion of Antibody Specificity Is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine	205
Introduction	205
Structure-Based RV Paradigm in HIV-1 Vaccine Research	206
Unwarranted Assumptions of the Structure-Based RV Paradigm	207
Overlooking the Need for Antibody Affinity Maturation to Obtain Effective Anti HIV-1 Neutralizing Abs	208
Reliance on Reductionist Thinking: Another Pitfall of the Structure-Based RV Paradigm	210
The Structure-Based RV Paradigm Suffers from Another Major Misguided Assumption, Namely an Outdated Notion of Ab Specificity	210
Causes, Explanations, and Understanding in Vaccinology	213
Conclusion	215
More Surprises in the Development of an HIV Vaccine (General Commentary)	217
Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 Not Inform the Rational Design of an HIV-1 Vaccine?	221
Introduction	221
The Antibody Response to the HIV-1 Envelope Glycoprotein Complex (Env)	223
Dissecting the Antigenic Structure of HIV-1 with Mabs Has Unforeseen Consequences	225
What Does It Mean to Rationally Design an HIV-1 Vaccine?	226
Conclusions	228
Old and New Concepts and Strategies in HIV Vaccinology: A Report from a Workshop Held in Rome on 17 June 2016	229
Introduction	229
Question 1: What New Approaches Should Be Followed in HIV-1 Vaccinology?	231
Question 2: Should HIV-1 Inactivation Be Reconsidered?	238
Question 3: Can Therapeutic Vaccines Help the Development of Preventative Vaccines? Should Therapeutic Testing Precede Testing in Healthy People?	240
Question 4: Do You Think That Therapeutic Vaccines Could Lead to a Functional Cure?	242
Question 5: If You Had the Authority to Do It, What Vaccine Concepts Would You Support for Testing?	245
Concluding Remarks	247

Structure-Based Reverse Vaccinology Failed in the Case of HIV Because It Disregarded Accepted Immunological Theory	249
Introduction	249
Genome-Based and Structure-Based Reverse Vaccinology	250
Structural Vaccinology	250
Structure and Dynamics of Epitopes and Paratopes	252
Discontinuous Epitopes	252
Continuous Epitopes	258
Mimotopes	259
Paratopes	260
The So-Called Rational Design of HIV-1 Vaccine Immunogens	261
What Do Vaccinologists Actually Do When They Claim to be Rationally Designing an HIV-1 Vaccine?	262
Rational Vaccine Design Without a Designer Is Only a Metaphor	263
Paradigms in HIV Vaccinology	263
An Effective HIV-1 Vaccine Cannot Be Developed by Disregarding Accepted Immunological Theory	266
Facts, Hypotheses, Laws, Theories, and Empirical Experimentation	266
Degeneracy of the Immune System and Polyspecificity of Antibodies	268
Structural and Functional Analyses Delineate Different Epitopes	271
The Immunogenicity of a Protein Molecule Is a Complex Biological Property that Cannot Be Predicted from the Molecule's Antigenicity, Which Is Simply Its Ability to Bind Certain Immunoglobulins	274
Conclusions	275
Immune Systems Rather than Antigenic Epitopes Elicit and Produce Protective Antibodies Against HIV	279
Letter to the Editor	279
Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design	283
Introduction	283
What are Inverse Problems?	285
Can Systems Biology Help Solve Inverse Problems in Vaccinology?	286
Reductionist Thinking and Invalid Paradigms Have Hampered Attempts to Develop an HIV-1 Vaccine	288
What Is Structure-Based Reverse Vaccinology (SBRV)?	290
The Bottleneck of Stochastic Ab Affinity Maturation	293
Can Rational HIV Vaccine Design Overcome the Limits of Bounded Rationality?	294
The Use of Transmitted/Founder Virus as HIV Vaccine Immunogen	296
Conclusion	298

Viral Species, Viral Genomes and HIV Vaccine Design: Is the Rational Design of Biological Complexity a Utopia?	299
Virus Species and Classification	299
Are Virus Species Polythetic Classes or Monophyletic Groups?	301
A Philosophical Interlude: Bionominalism Regards Species as Concrete Individuals Rather than Conceptual Classes	305
Is it Possible to Incorporate Viral Metagenomic Data in the Current ICTV System of Virus Classification Established Using the Chemical and Biological Properties of Viruses?	306
It Is Rarely Possible to Infer the Phenotypic Properties of a Virus from its Genome Sequence	307
Determinism, Contingency and Complexity	308
HIV Vaccine Design	309
 Conclusion: The Rational Design of a Preventive HIV Vaccine is a Utopia	 311
 References	 315

About the Author

Marc H V Van Regenmortel was a Professor of Virology at various universities in South Africa (Stellenbosch and Cape Town) and France (Strasbourg) and was head of the Immunochemistry Laboratory at the CNRS Molecular Biology Institute in Strasbourg for 22 years. He served as President of the International Committee on Taxonomy of Viruses and published a dozen books and 420 papers and reviews on the immunochemistry of peptides and viruses, viral taxonomy, and biosensor technology. He was an advisor to the South African AIDS Vaccine Initiative and is currently an associate editor of *Journal of Molecular Recognition*, *Archives of Virology*, *Advances in Virus Research*, *Journal of Immunological Methods*, *Analytical Biochemistry*, and *Frontiers in Immunology*.

He is an Adjunct Professor of the Medical University of Vienna.